Tranexamic Acid for Heavy Menstrual Bleeding: Dosing and Risk-Benefit Profile
For a premenopausal woman with heavy menstrual bleeding and iron deficiency anemia, prescribe tranexamic acid 1.3 grams orally three times daily (total 3.9 g/day) for up to 5 days during menstruation, starting on the first day of bleeding. This regimen significantly reduces menstrual blood loss by 40-60%, improves hemoglobin and ferritin levels, and enhances quality of life with minimal risk 1, 2.
Prescribing Algorithm
Initial Assessment
- Confirm heavy menstrual bleeding (>80 mL per cycle or patient-reported excessive bleeding interfering with quality of life)
- Document iron deficiency anemia: hemoglobin <12 g/dL and/or ferritin <30 μg/L 3
- Screen for contraindications: active thromboembolic disease, history of thrombosis/thromboembolism, subarachnoid hemorrhage, or severe renal impairment 4
Dosing Regimen
Standard dose: Tranexamic acid 1.3 g orally three times daily (3.9 g/day total) for up to 5 days per menstrual cycle 5, 1
- Start on day 1 of menstrual bleeding
- Continue for duration of heavy flow (typically 3-5 days)
- Repeat each menstrual cycle as needed
Renal dose adjustments 4:
- Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
- Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
- Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours
Concurrent Iron Replacement
Do not defer iron therapy while initiating tranexamic acid 6. Start oral iron supplementation immediately:
- Ferrous sulfate, fumarate, or gluconate: one tablet daily (or every other day if not tolerated) 6
- Continue for approximately 3 months after hemoglobin normalizes to replenish iron stores 6
- Consider intravenous iron if oral iron is ineffective, poorly tolerated, or if severe anemia requires rapid correction 7
Benefits
Bleeding Reduction
- 40% mean reduction in menstrual blood loss compared to 8% with placebo 1
- 69.6 mL absolute reduction in blood loss per cycle 1
- Significantly more effective than NSAIDs, oral progestins, or etamsylate 8
Hematologic Improvement
- Mean hemoglobin increase of ≥0.71 g/dL after 3 cycles in women with baseline Hgb <12 g/dL 2
- 45.7% of anemic women achieved normal hemoglobin after 27 cycles 2
- Mean ferritin increase >5.38 ng/mL after 15-27 cycles 2
- 58% of women with low ferritin (<10 ng/mL) normalized levels after 27 cycles 2
Quality of Life
Significant improvements in 1:
- Physical activities and exercise capacity
- Work productivity (inside and outside home)
- Social and leisure activities
- Sexual intimacy 3
Risks and Safety Profile
Thromboembolic Risk
The most significant concern is thrombosis, though actual incidence is low 4:
- Contraindicated in active thromboembolic disease 4
- FDA labeling includes contraindication for history of thrombosis or intrinsic thrombotic risk 4
- However, no evidence of increased thrombotic events in clinical trials for heavy menstrual bleeding [8, @30@]
- Avoid concomitant use with prothrombotic medications (Factor IX concentrates, hormonal contraceptives) 4
Critical distinction: The 2025 French emergency medicine guidelines note that tranexamic acid for heavy menstruation is effective "without increasing the risk of venous thromboembolism" 9. The thrombotic risk appears theoretical rather than clinically significant in this population.
Common Adverse Effects
Mild to moderate and comparable to placebo 1, 10:
- Menstrual discomfort
- Headache
- Back pain
- Gastrointestinal symptoms (nausea, diarrhea) - not significantly increased vs placebo 1
Serious Adverse Events
- Seizures: Only with inadvertent intrathecal administration (not applicable to oral formulation) 4
- Hypersensitivity reactions: Rare; discontinue if severe reaction occurs 4
- Visual disturbances: Discontinue if ocular symptoms develop 4
Clinical Pitfalls to Avoid
Don't delay iron replacement: Start oral or IV iron concurrently with tranexamic acid 6. Tranexamic acid reduces bleeding but doesn't replace depleted iron stores.
Don't use lower doses: The 1.95 g/day dose failed to meet efficacy endpoints 11. The 3.9 g/day dose is necessary for optimal benefit.
Don't prescribe continuously: Tranexamic acid is taken only during menstruation (up to 5 days), not throughout the entire cycle 5, 1.
Don't overlook renal function: Dose reduction is mandatory in renal impairment to prevent accumulation 4.
Don't assume thrombotic risk equals contraindication: While FDA labeling is conservative, clinical trial data shows no increased thrombotic events in women with heavy menstrual bleeding [8, @30@]. Evaluate individual risk factors rather than blanket exclusion.
Monitoring and Follow-Up
- Check hemoglobin at 4 weeks to assess response 6
- Monitor ferritin levels to guide duration of iron therapy 6
- Reassess bleeding patterns after 3 cycles
- If inadequate response after 3-6 cycles, consider alternative or additional therapies (hormonal contraceptives, levonorgestrel IUD) 5
Alternative Considerations
If tranexamic acid is ineffective or contraindicated 5:
- NSAIDs (ibuprofen, mefenamic acid): 5-7 days during menstruation - less effective than tranexamic acid 12
- Hormonal contraceptives: Combined oral contraceptives or levonorgestrel IUD - more effective than tranexamic acid but with different side effect profile 5
- Procedural options: Endometrial ablation for completed fertility 13